Effects of inhibition of urokinase-type plasminogen activator (u-PA) by amiloride in the cornea and tear fluid of eyes irradiated with UVB.
暂无分享,去创建一个
[1] M. Crippa. Urokinase-type plasminogen activator. , 2007, The international journal of biochemistry & cell biology.
[2] J. Čejková,et al. Dipeptidyl peptidase IV (DPPIV) activity in the tear fluid as an indicator of the severity of corneal injury: a histochemical and biochemical study. , 2004, Histology and histopathology.
[3] D. Collen,et al. Tissue‐type plasminogen activator: a historical perspective and personal account , 2004, Journal of thrombosis and haemostasis : JTH.
[4] J. Čejková,et al. UV Rays, the prooxidant/antioxidant imbalance in the cornea and oxidative eye damage. , 2004, Physiological research.
[5] J. Hoover-Plow,et al. The role of plasminogen in angiogenesis in vivo , 2003, Journal of thrombosis and haemostasis : JTH.
[6] T. Nishida,et al. Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding. , 2003, Investigative ophthalmology & visual science.
[7] P. Carmeliet,et al. Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis , 2002, Arthritis research & therapy.
[8] L. Rhodes,et al. UVR-induced oxidative stress in human skin in vivo: effects of oral vitamin C supplementation. , 2002, Free radical biology & medicine.
[9] C. Noorden. Direct comparison of enzyme histochemical and immunohistochemical methods to localize an enzyme , 2002 .
[10] K. K. Saxena,et al. Topical amiloride solution accelerates healing of mechanical skin ulcers in albino rats. , 2000, Methods and findings in experimental and clinical pharmacology.
[11] J. Tözsér,et al. Plasminogen activator activity in tears after excimer laser photorefractive keratectomy. , 2000, Investigative ophthalmology & visual science.
[12] A. K. Sood,et al. Topical amiloride accelerates healing and delays neovascularization in mechanically produced corneal ulcers in rabbits. , 1999, Methods and findings in experimental and clinical pharmacology.
[13] E. Skrzypczak‐Jankun,et al. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. , 1999, Cancer biochemistry biophysics.
[14] J. Zvárová,et al. Comparative histochemical and biochemical studies on acid beta-galactosidase activity in the experimentally injured rabbit cornea and tear fluid using the sensitive substrate beta-galactoside-4-trifluoromethylumbelliferyl (HFC). , 1999, Histology and histopathology.
[15] Z. Lojda. The use of substrates with 7-amino-3-trifluoromethylcoumarine (AFC) leaving group in the localization of protease activities in situ. , 1996, Acta histochemica.
[16] J. Čejková,et al. The appearance of active plasminogen activator of urokinase type (u-PA) in the rabbit anterior eye segment irradiated by UVB rays. A histochemical and biochemical study. , 1995, Acta histochemica.
[17] J. Čejková,et al. The damaging effect of UV rays below 320 nm on the rabbit anterior eye segment. II. Enzyme histochemical changes and plasmin activity after prolonged irradiation. , 1995, Acta histochemica.
[18] H. Petty,et al. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium. , 1995, Journal of immunology.
[19] B. Eley,et al. Comparative histochemical, biochemical and immunocytochemical studies of cathepsin B in human gingiva. , 1994, Journal of periodontal research.
[20] J. Čejková,et al. Biochemical and histochemical studies of plasminogen activator of urokinase type (u-PA) activity. I. A simple rapid semiquantitative fluorescent method for its detection in the tear fluid. , 1993, Acta histochemica.
[21] T. Nishida,et al. Role of Urokinase Type Plasminogen Activator (u-PA) in Corneal Epithelial Migration , 1993, Thrombosis and Haemostasis.
[22] A. Vaheri,et al. REGULATION OF THE PERICELLULAR ACTIVATION OF PLASMINOGEN AND ITS ROLE IN TISSUE‐DESTRUCTIVE PROCESSES , 1992, Acta ophthalmologica. Supplement.
[23] F. Kaneko,et al. Changes in lipid peroxide levels and activity of reactive oxygen scavenging enzymes in skin, serum and liver following UVB irradiation in mice. , 1992, Life sciences.
[24] J. Pelletier,et al. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. , 1991, The Journal of rheumatology.
[25] K. Kenyon,et al. Pathogenesis of corneal epithelial defects: role of plasminogen activator. , 1991, Current eye research.
[26] J. Calvete,et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). , 1991, The Journal of biological chemistry.
[27] R. Tripathi,et al. Localization of urokinase-type plasminogen activator in human eyes: an immunocytochemical study. , 1990, Experimental eye research.
[28] J. Tözsér,et al. Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva , 1990, Acta ophthalmologica.
[29] R. Avery,et al. Systemic amiloride inhibits experimentally induced neovascularization. , 1990, Archives of ophthalmology.
[30] F. Semeraro,et al. Analysis of fibronectin, plasminogen activators and plasminogen in tear fluid as markers of corneal damage and repair. , 1990, Experimental eye research.
[31] R. Nordquist,et al. Role of active oxygen species in corneal ulceration. Effect of hydrogen peroxide generated in situ. , 1990, Cornea.
[32] J. Tözsér,et al. Plasminogen activator activity and plasminogen independent amidolytic activity in tear fluid from healthy persons and patients with anterior segment inflammation. , 1989, Clinica chimica acta; international journal of clinical chemistry.
[33] P. Neumann,et al. Evidence for regulation of endothelial plasminogen-activating system by polymorphonuclear leukocyte elastase. , 1989, Thrombosis research.
[34] M. Berman. The pathogenesis of corneal epithelial defects , 1989, Acta ophthalmologica. Supplement.
[35] A. Vaheri,et al. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants , 1989, The Journal of cell biology.
[36] R. Tripathi,et al. Distribution of tissue plasminogen activator in human and monkey eyes. An immunohistochemical study. , 1987, Ophthalmology.
[37] P. Gudewicz,et al. Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. , 1987, Biochemical and biophysical research communications.
[38] A. Gee,et al. Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. , 1987, Journal of immunology.
[39] D. Belin,et al. Amiloride selectively inhibits the urokinase‐type plasminogen activator , 1987, FEBS letters.
[40] F. Blasi,et al. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors , 1987, The Journal of cell biology.
[41] K. Fujikawa,et al. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. , 1986, The Journal of biological chemistry.
[42] R. Stephens,et al. Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator , 1981, International journal of cancer.
[43] A. Pearse. Histochemistry: Theoretical and Applied , 1953 .